• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » CRL announces planned management changes

CRL announces planned management changes

March 4, 2015
CenterWatch Staff

Massachusetts-based Charles River Laboratories International has announced planned management changes to be implemented over the course of 2015.

Following a transition period, Thomas F. Ackerman, corporate executive vice president and chief financial officer, will retire in February 2016. Ackerman joined Charles River in 1988 and became vice president and chief financial officer in 1996, elevated to his current position in 2005. He will provide periodic consulting services for one year following his retirement.

David R. Smith, corporate senior vice president, global discovery services, has been named Ackerman's successor. Smith joined Charles River through its acquisition of Argenta and BioFocus from Galapagos, where he was CEO of the Galapagos Services division. Smith spent eight years at PricewaterhouseCoopers before joining AstraZeneca in 1997.

Once Smith assumes his new role, Dr. Emily Hickey will be promoted to corporate senior vice president, global discovery services. Before joining Charles River, Hickey was executive director of in vivo pharmacology at Merck Research Labs, leading development and implementation of the externalization strategy for in vivo studies. Most recently, she was corporate vice president, in vivo discovery, overseeing CRL’s businesses in the U.S. and Europe. Dr. Katherine Hilyard, managing director, BioFocus DPI, will be promoted to corporate vice president, early discovery, assuming responsibility for the Argenta, BioFocus and ChanTest businesses.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing